Raymond James Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $14

Benzinga · 1d ago
Raymond James analyst Tiago Fauth initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $14.